img

Bristol-Myers Squibb completes acquisition of IFM Therapeutics

Bristol-Myers Squibb Company has announced that it has completed the previously announced planned acquisition of IFM Therapeutics.

Sharing is caring, show love and share the thread with your friends.

Description

The transaction includes full rights to IFM’s preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer. IFM’s STING agonist program includes a lead asset that accelerates the company’s efforts against this target, while the NLRP3 agonist program includes a potential first-in-class pipeline candidate. A newly formed entity will be established by the current shareholders of IFM - IFM Therapeutics LLC – and it will retain IFM’s current personnel and facilities, as well as its remaining research programs, which include an NLRP3 antagonist program focused on curbing immune responses that lead to inflammatory diseases and fibrosis.

Tags

Bristol-myers squibb completes acquisition, ifm therapeutics

References

View / Download